Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.49 |
| ▸ | PPP5C | P53041 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2975112 | 0.90 | EPHX2 (0.54) | EPHX2CNR1CNR2SMYD3 | |
| SCHEMBL2975107 | 0.90 | EPHX2 (0.54) | EPHX2CNR1CNR2SMYD3 | |
| SCHEMBL22729658 | 0.89 | EPHX2 (0.43) | EPHX2PPP5CCNR1CNR2 | |
| SCHEMBL21403868 | 0.85 | GABRA1 (0.36) | EPHX2SMYD3GAA | |
| SCHEMBL29839284 | 0.81 | BTK (0.48) | EPHX2GAA | |
| SCHEMBL25375425 | 0.76 | EPHX2 (0.43) | EPHX2SMYD3SMN1; SMN2 | |
| SCHEMBL8970567 | 0.76 | PPP5C (0.43) | EPHX2PPP5CMAPK1 | |
| SCHEMBL5003553 | 0.75 | FFAR4 (0.41) | SMN1; SMN2 | |
| SCHEMBL16405165 | 0.75 | EPHX2 (0.41) | EPHX2PPP5CCNR1CNR2 | |
| SCHEMBL5003551 | 0.75 | FFAR4 (0.41) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | EPHX2 2093/4885PPP5C 1017/4885CNR1 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.